Characteristics and outcomes of asthmatic outpatients with COVID-19 who receive home telesurveillance
- Antoine Beurnier1,
- Youri Yordanov2,
- Agnès Dechartres3,
- Aurélien Dinh4,
- Erwan Debuc5,
- François-Xavier Lescure6,7,
- Patrick Jourdain8,9,
- Luc Jaulmes10 and
- Marc Humbert11⇑
- 1Université Paris-Saclay, Faculty of Medicine, INSERM UMR_S 999, Service de physiologie et d'explorations fonctionnelles respiratoires, CRISALIS/F-CRIN network, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
- 2Sorbonne Université, AP-HP, Hôpital Saint Antoine, Service d'Accueil des Urgences, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR-S 1136, Paris, France
- 3Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR-S 1136, AP-HP.Sorbonne Université, Hopital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmaco-épidémiologie de l'AP-HP (Cephepi), Paris, France
- 4Infectious Disease Department, R. Poincaré University Hospital, Garches, APHP, Paris Saclay University, Paris, France
- 5Assistance Publique-Hopitaux de Paris, Paris, France
- 6Department of Infectious and Tropical Diseases, APHP, Bichat-Claude Bernard University Hospital, Paris, France
- 7Infections Antimicrobials Modelling Evolution (IAME), UMR 1137, University of Paris, Paris, France
- 8DMU COREVE, GHU Paris Saclay, APHP, Paris, France
- 9INSERM UMR S 999, IHU TORINO (thorax Innovation), Italy
- 10AP-HP.Sorbonne Université, Hopital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmaco-épidémiologie de l'AP-HP (Cephepi), Paris, France
- 11Université Paris-Saclay, Faculty of Medicine, INSERM UMR_S 999, AP-HP, Service de pneumologie et soins intensifs respiratoires, CRISALIS/F-CRIN network, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
- Pr. Marc Humbert, MD, PhD, Department of Respiratory and Intensive Care Medicine, 78 rue du général Leclerc, 94270 Le Kremlin Bicêtre, France. E-mail: marc.humbert{at}aphp.fr
Abstract
Background The prognosis of asthmatic outpatients with COVID-19 needs to be clarified. The objectives of this study were 1) to investigate the characteristics and outcomes of asthmatics receiving initial ambulatory care and home monitoring for COVID-19 with Covidom, a telesurveillance solution and 2) to compare the characteristics and outcomes between asthmatics and non-asthmatics.
Methods Inclusion criteria were age ≥18 years, suspected or confirmed COVID-19 diagnosis allowing initial ambulatory care, registration in Covidom between March 2020 and April 2021, completion of the initial medical questionnaire. We compared clinical characteristics and outcomes between asthmatics and non-asthmatics and we evaluated whether asthma was independently associated with clinical worsening (hospitalisation or death) within 30 days follow-up using a multivariate logistic regression model.
Results 33 815 patients met the inclusion criteria. Asthma was reported in 4276 (12.6%). The main comorbidities among asthmatics were obesity (23.1%), hypertension (12.7%) and diabetes (4.5%). As compared with non-asthmatics, asthmatics were more often female (70.0 versus 62.1%, p<0.001), of younger age (42.2 versus 43.8 years, p<0.001) and obese (23.1 versus 17.6%, p<0.001). The rate of hospitalisation did not differ significantly (4.7 versus 4.2%, p=0.203) and no asthmatic patient died during follow-up (versus 25 non-asthmatics, 0.1%; p=0.109). In multivariate analysis, asthma was independently associated with higher risk of clinical worsening (OR=1.23 (1.04–1.44), p=0.013).
Conclusion In a large French cohort of patients receiving initial ambulatory care and home monitoring for COVID-19, asthma was independently associated with higher risk of clinical worsening although no asthmatic patient died within the 30 days follow-up.
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Beurnier reports personal fees from AstraZeneca, personal fees from Sanofi outside the submitted work.
Conflict of interest: Youri Yordanov have nothing to disclose.
Conflict of interest: Agnès Dechartres have nothing to disclose.
Conflict of interest: Aurélien Dinh have nothing to disclose.
Conflict of interest: Erwan Debuc have nothing to disclose.
Conflict of interest: François-Xavier Lescure have nothing to disclose.
Conflict of interest: Patrick Jourdain have nothing to disclose.
Conflict of interest: Luc Jaulmes have nothing to disclose.
Conflict of interest: Pr. Humbert reports personal fees and non-financial support from GlaxoSmithKline, personal fees from Astrazeneca, personal fees from Novartis, personal fees from Sanofi, personal fees from Chiesi, outside the submitted work.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received January 7, 2022.
- Accepted July 23, 2022.
- Copyright ©The authors 2022
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org